[go: up one dir, main page]

CN1074922C - 含有帕罗西汀树脂酸盐的口服液体组合物 - Google Patents

含有帕罗西汀树脂酸盐的口服液体组合物 Download PDF

Info

Publication number
CN1074922C
CN1074922C CN95191483A CN95191483A CN1074922C CN 1074922 C CN1074922 C CN 1074922C CN 95191483 A CN95191483 A CN 95191483A CN 95191483 A CN95191483 A CN 95191483A CN 1074922 C CN1074922 C CN 1074922C
Authority
CN
China
Prior art keywords
paroxetine
pharmaceutical composition
agent
depression
exchange resin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN95191483A
Other languages
English (en)
Other versions
CN1140411A (zh
Inventor
G·S·里昂纳德
D·库帕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of CN1140411A publication Critical patent/CN1140411A/zh
Application granted granted Critical
Publication of CN1074922C publication Critical patent/CN1074922C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

一种含有帕罗西汀—弱酸性阳离子交换树脂AmberliteIRP-88弱酸性阳离子交换树脂配合物的口服液体药物组合物。

Description

含有帕罗西汀树脂酸盐的口服液体组合物
本发明涉及新配方以及这种配方在治疗和/或预防某些疾病方面的用途。
美国专利4,007,196公开了某些具有抗抑郁剂活性的化合物。该专利中提到的一种具体化合物称为帕罗西汀，其结构式如下：
Figure C9519148300031
该化合物已被认可用于人体，并作为一种抗抑郁剂在全球许多国家销售。
迄今为止所有帕罗西汀均以口服吞下药片形式销售。
许多医生一直表示希望能开出一种含有帕罗西汀的口服液处方，而且有一些医生甚至将普通的吞服药片粉碎，再与水混，由此自制了口服液。然而，这种口服液有许多缺点，首先帕罗西汀具有很强的苦味，以口服液形式投药时这种苦味特别明显，其次，这种口服液稳定性差，贮存期仅有几天。
WO 91/13612涉及缓释药物，这种药物使用了其中药物与一种离子交换树脂配合的组合物。在该公开的专利申请中所述的具体的离子交换树脂是Amberlite IRP-69。
当用Amberlite IRP-69与帕罗西汀配合时就发现，虽然这种苦味能有效地掩盖，但是与吞服药片相比，这种组合物的生物利用率低得不可接受。
现已发现，可用一种商品名为Amberlite IRP-88的弱酸性阳离子交换树脂与帕罗西汀来制成一种无苦味稳定配合物，而且与传统的吞服药片相比时，这种配合物具有可接受的生物利用率。Amberlite IRP-88树脂是一种钾盐形式的丙烯酸与二乙烯基苯的交联聚合物。
因此，本发明提供一种含有帕罗西汀-Amberlite IRP-88配合物的口服液体药物组合物。
Amberlite IRP-88可从Rohm & Hass公司按药物可接受级购得。
本发明的口服液体药物组合可用传统的方法制备，例如，可将帕罗西汀与Amberlite IRP-88一起混合在一种含水介质中。IRP-88与帕罗西汀的用量比为1∶1-2∶1较为合适。应该指出的是，采用2∶1的比例时可以获得优异的掩善苦味的效果。
也可以添加其它药物上可接受的赋形剂，例如增稠剂如Keltrol和/或Avicel(尤其Avicel CL 611)；分散剂如丙二醇；保湿剂如甘油；甜味剂如山梨糖醇和糖精钠；缓冲剂如柠檬酸和柠檬酸钠；防腐剂如苯甲酸钠和对羟基苯甲酸甲酯和丙酯的混合物；合成着色剂如FD和C黄6号、日落(Sunset)黄；香味剂如Givaudan天然橙和/或柠檬；以及消泡剂如硅氧烷消泡剂。
缓冲剂的用量较好控制在能得到pH4-6，最好pH4.5-6.0。
帕罗西汀的用量应调节到在一个单位剂量中含有治疗有效量的帕罗西汀。单位剂量较好含有10-100mg帕罗西汀(按游离碱测定)。单位剂量中帕罗西汀含量更好地是10mg、20mg、30mg、40mg或50mg。单位剂量中帕罗西汀含量最好为20mg。单位剂量中液体的体积较好为5-20ml，最好为10ml。
该配方中所用的帕罗西汀较好是呈盐酸盐半水合物形式，可按美国专利4,721,723所述方法制备。
制备帕罗西汀的合适方法包括美国专利4,009,196、4,902,801、4,861,893和5,039,803以及PCT/GB 93/00721中提及的那些方法。
已经提到帕罗西汀在治疗抑郁症方面特别有用，帕罗西汀也可用于治疗混合型焦虑症和抑郁症、强迫观念与行为的疾病、恐慌、疼痛、肥胖、老年痴呆、偏头痛、食欲过盛、厌食、社交恐怖症以及起因于经前紧张和青春期的抑郁症。
因此本发明也提供一种治疗或预防上述任何疾病的方法，该方法包括对需要这种治疗和预防的患者施用有效量或预防量的含有帕罗西汀-Amberlite IRP-88配合物的口服液体药物组合物。
本发明还提供含有帕罗西汀-Amberlite IRP-88配合物的口服液体药物组合物在制造用于治疗或预防上述疾病的药物方面的用途。
本发明还进一步提供用于治疗或预防上述疾病的药物组合物，该组合物包括掺合了药物上可接受的载体的帕罗西汀-Amberlite IRP-88配合物。
下面的实例说明本发明：
实例1 Amberlite IRP-88与帕罗西汀的比例为1∶1
                                      mg/10ml
帕罗西汀盐酸盐                         22.8
Amberlite IRP-88(＜63μm)              22.8
Keltrol                                40.0
丙二醇                                 350.0
甘油                                   350.0
山梨糖醇(70％)                         4000.0
柠檬酸                                 15.0
柠檬酸钠                               10.0
苯甲酸钠                               10.0
糖精钠                                 5.0
日落(Sunset)黄                         0.5
Givaudan天然橙                         1.0
Givaudan天然柠檬                       2.0
硅氧烷消泡剂                           20.0
水                                 加至10.0
实例2 Amberlite IRP与帕罗西汀的比例为2∶1
                                      mg/10ml
帕罗西汀盐酸盐(＜180微米)              22.8
Amberlite IRP-88(＜200目)              40.0*
Avicel CL 611                          300.0
丙二醇                                 500.0
甘油                                   500.0
山梨糖醇(70％)                         4000.0
柠檬酸(无水)                           15.0
柠檬酸钠(二水合物)                     10.0
对羟基苯甲酸甲酯              20.0
对羟基苯甲酸丙酯              6.0
糖精钠                        5.0
FD & C黄6号                   0.9
Givaudan天然橙74388-74        1.0mol
Givaudan天然柠檬74940-74      2.0mol
硅氧烷消泡剂1510              20.0
水                        加至10.0
*以干基计。
实例3
与上面一样，但用300mg Avicel CL 611代替40.0mg。
实例4
与上面一样，但使用15mg Keltrol和300mg Avicel CL 611。

Claims (10)

1．一种含有帕罗西汀弱酸性阳离子交换树脂Amberlite IRP-88配合物的口服药物组合物。
2．制备权利要求1定义的药物组合物的方法，该方法包括将帕罗西汀和弱酸性阳离子交换树脂Amberlite IRP-88一起混合在含水介质中。
3．按照权利要求2的方法，其中弱酸性阳离子交换树脂IRP-88与帕罗西汀的摩尔比为1∶1-2∶1。
4．按照权利要求1的药物组合物，其中加入下列一种或多种添加剂：增稠剂、分散剂、保湿剂、甜味剂、缓冲剂、防腐剂、合成着色剂、香味剂以及消泡剂。
5．按照权利要求4的药物组合物，其中缓冲剂的用量应控制在能得到pH4-6的范围。
6．按照权利要求1,4或5中任何一项的药物组合物，其形式为单位剂量。
7．按照权利要求6的药物组合物，其中所述单位剂量中帕罗西汀的含量为10mg、20mg、30mg、40mg或50mg。
8．按照权利要求1、4或5中任何一项的药物组合物，其中所述的帕罗西汀呈盐酸盐半水水合物形式。
9．如权利要求1定义的含有帕罗西汀-弱酸性阳离子交换树脂Amberlite IRP-88配合物的口服液体药物组合物在制造用于治疗或预防混合型焦虑症和抑郁症、强迫观念与行为疾病、恐慌症、疼痛、肥胖、老年痴呆、偏头痛、食欲过盛、厌食、社交恐怖症以及起因于经前紧张和青春期的抑郁症的药物方面的用途。
10．一种用于治疗或预防混合型焦虑症和抑郁症、强迫观念与行为疾病、恐慌症、疼痛、肥胖、老年痴呆、偏头痛、食欲过盛、厌食、社交恐怖症以及起因于经前紧张和青春期的抑郁症的如权利要求1定义的药物组合物。
CN95191483A 1994-02-03 1995-01-30 含有帕罗西汀树脂酸盐的口服液体组合物 Expired - Fee Related CN1074922C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9402029A GB9402029D0 (en) 1994-02-03 1994-02-03 Novel formulation
GB9402029.4 1994-02-03

Publications (2)

Publication Number Publication Date
CN1140411A CN1140411A (zh) 1997-01-15
CN1074922C true CN1074922C (zh) 2001-11-21

Family

ID=10749765

Family Applications (1)

Application Number Title Priority Date Filing Date
CN95191483A Expired - Fee Related CN1074922C (zh) 1994-02-03 1995-01-30 含有帕罗西汀树脂酸盐的口服液体组合物

Country Status (34)

Country Link
US (1) US5811436A (zh)
EP (1) EP0742715B1 (zh)
JP (1) JP4445590B2 (zh)
CN (1) CN1074922C (zh)
AP (2) AP611A (zh)
AT (1) ATE178489T1 (zh)
AU (1) AU682091B2 (zh)
BG (1) BG62843B1 (zh)
BR (1) BR9507055A (zh)
CA (1) CA2182593A1 (zh)
CZ (1) CZ285128B6 (zh)
DE (1) DE69508924T2 (zh)
DK (1) DK0742715T3 (zh)
DZ (1) DZ1850A1 (zh)
ES (1) ES2129806T3 (zh)
FI (1) FI118205B (zh)
GB (1) GB9402029D0 (zh)
GR (1) GR3030131T3 (zh)
HK (1) HK1012288A1 (zh)
HU (1) HUT75941A (zh)
IL (1) IL112521A (zh)
MA (1) MA23441A1 (zh)
MX (1) MX9603203A (zh)
MY (1) MY113036A (zh)
NO (1) NO307954B1 (zh)
NZ (1) NZ278891A (zh)
OA (1) OA10446A (zh)
PL (1) PL178331B1 (zh)
RO (1) RO116342B1 (zh)
RU (1) RU2136281C1 (zh)
SK (1) SK281214B6 (zh)
TW (1) TW436296B (zh)
WO (1) WO1995020964A1 (zh)
ZA (1) ZA95776B (zh)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
EP1078925A1 (en) 1997-06-10 2001-02-28 Synthon B.V. 4-Phenylpiperidine compounds
US6699882B2 (en) 1998-03-24 2004-03-02 Smithkline Beecham P.L.C. Paroxetine compositions
DK172860B1 (da) * 1998-03-25 1999-08-16 Pharmacosmos Holding As Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernman
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
US6660298B1 (en) * 2000-07-27 2003-12-09 Pentech Pharmaceuticals, Inc. Paroxetine tablets and capsules
US6720003B2 (en) * 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
EP1250937B1 (en) * 2001-04-09 2009-05-13 Rohm And Haas Company Controlled dissolution of active ingredients
US20020176842A1 (en) * 2001-04-09 2002-11-28 Lyn Hughes Extended release of active ingredients
US6906206B2 (en) * 2001-04-30 2005-06-14 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene
GB0119467D0 (en) * 2001-08-09 2001-10-03 Smithkline Beecham Plc Novel compound
US20040242497A1 (en) * 2001-08-09 2004-12-02 Barges Causeret Nathalie Claude Marianne Composition comprising paroxetine and a pharmaceutically acceptable glycyrrhizinate salt
US6939877B2 (en) * 2002-09-12 2005-09-06 Wyeth Antidepressant piperidine derivatives of heterocycle-fused benzodioxans
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20050036977A1 (en) * 2003-08-11 2005-02-17 Dilip Gole Taste-masked resinate and preparation thereof
US20050266082A1 (en) * 2004-05-26 2005-12-01 Patel Satishkumar A Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
US20060063737A1 (en) * 2004-08-18 2006-03-23 Holmdahl Lisa K Liquid paroxetine compositions
EP1791531A1 (en) * 2004-08-20 2007-06-06 Alpharma, Inc. Paroxetine formulations
KR100672184B1 (ko) * 2004-09-21 2007-01-19 주식회사종근당 파록세틴의 콜린산 또는 콜린산 유도체 염
CA2629514A1 (en) * 2005-11-14 2007-05-24 Auspex Pharmaceuticals, Inc. Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
CN102430122A (zh) * 2005-12-13 2012-05-02 量子高科（北京）研究院有限公司 盐酸氟西汀口腔崩解片及其制备方法
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
US20100273822A1 (en) * 2009-04-22 2010-10-28 William Wayne Howard Immediate release compositions and methods for delivering drug formulations using strong acid ion exchange resins
US8758779B2 (en) 2009-06-25 2014-06-24 Wockhardt Ltd. Pharmaceutical composition of duloxetine
US8187617B2 (en) * 2009-09-11 2012-05-29 William Wayne Howard Immediate release compositions and methods for delivering drug formulations using weak acid ion exchange resins in abnormally high pH environments
EP2572717B1 (en) 2010-05-19 2016-06-15 Astellas Pharma Inc. Pharmaceutical composition containing solifenacin
CN104027306A (zh) * 2014-06-25 2014-09-10 万特制药(海南)有限公司 帕罗西汀口服混悬液及其制备方法
GB201419261D0 (en) 2014-10-29 2014-12-10 Therakind Ltd Formulations
CN104382870A (zh) * 2014-10-30 2015-03-04 万全万特制药江苏有限公司 一种含有波拉克林钾-帕罗西汀的复合物
CN106309363A (zh) * 2016-09-24 2017-01-11 万特制药(海南)有限公司 盐酸帕罗西汀口服混悬液及其制备方法
CN108926528A (zh) * 2017-05-25 2018-12-04 北京万全德众医药生物技术有限公司 含有氨磺必利树脂酸盐的口服液体组合物
CA3128377A1 (en) 2019-02-01 2020-08-06 University Of South Carolina Bicyclic pyridine compositions and methods of using the same for cancer therapy
CN113209017B (zh) * 2021-06-02 2023-06-20 上海美优制药有限公司 一种盐酸帕罗西汀混悬剂及其制备方法
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2215233A1 (zh) * 1973-01-30 1974-08-23 Ferrosan As
WO1991013612A1 (en) * 1990-03-12 1991-09-19 Beecham Group Plc Composition

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1246188B (it) * 1990-07-27 1994-11-16 Resa Farma Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2215233A1 (zh) * 1973-01-30 1974-08-23 Ferrosan As
WO1991013612A1 (en) * 1990-03-12 1991-09-19 Beecham Group Plc Composition

Also Published As

Publication number Publication date
DE69508924T2 (de) 1999-10-21
US5811436A (en) 1998-09-22
SK100496A3 (en) 1996-12-04
BG100763A (bg) 1997-03-31
RU2136281C1 (ru) 1999-09-10
NO963244D0 (no) 1996-08-02
NZ278891A (en) 1998-01-26
AP611A (en) 1997-09-03
RO116342B1 (ro) 2001-01-30
DK0742715T3 (da) 1999-10-18
BR9507055A (pt) 1997-09-02
CN1140411A (zh) 1997-01-15
GR3030131T3 (en) 1999-07-30
ES2129806T3 (es) 1999-06-16
MA23441A1 (fr) 1995-10-01
BG62843B1 (bg) 2000-09-29
FI963051L (fi) 1996-08-01
MX9603203A (es) 1997-03-29
EP0742715B1 (en) 1999-04-07
HUT75941A (en) 1997-05-28
PL178331B1 (pl) 2000-04-28
AP9600839A0 (en) 1996-07-31
ZA95776B (en) 1996-08-01
NO963244L (no) 1996-08-02
WO1995020964A1 (en) 1995-08-10
CA2182593A1 (en) 1995-08-10
DE69508924D1 (de) 1999-05-12
AP9500715A0 (en) 1995-04-30
EP0742715A1 (en) 1996-11-20
IL112521A0 (en) 1995-05-26
HK1012288A1 (en) 1999-07-30
JP4445590B2 (ja) 2010-04-07
ATE178489T1 (de) 1999-04-15
SK281214B6 (sk) 2001-01-18
AU682091B2 (en) 1997-09-18
CZ229396A3 (en) 1997-01-15
DZ1850A1 (fr) 2002-02-17
CZ285128B6 (cs) 1999-05-12
OA10446A (en) 2002-03-26
PL315679A1 (en) 1996-11-25
HU9602151D0 (en) 1996-09-30
TW436296B (en) 2001-05-28
FI118205B (fi) 2007-08-31
NO307954B1 (no) 2000-06-26
IL112521A (en) 1999-09-22
GB9402029D0 (en) 1994-03-30
JPH09508402A (ja) 1997-08-26
AU1536895A (en) 1995-08-21
FI963051A0 (fi) 1996-08-01
MY113036A (en) 2001-11-30
AP536A (en) 1996-09-26

Similar Documents

Publication Publication Date Title
CN1074922C (zh) 含有帕罗西汀树脂酸盐的口服液体组合物
US6306904B1 (en) Antihistaminic/antitussive compositions
AU2003216399A1 (en) Diphenhydramine tannate liquid and semi-solid compositions and methods of use
NZ574148A (en) Phenylephrine liquid formulations comprising polyethylene glycol with low aldehyde content
JP2008143807A (ja) 感冒薬カプセル剤及びその製造方法
CA2372538A1 (en) Antitussive/antihistaminic/decongestant compositions
CN1179307A (zh) 液体抗酸剂组合物
US5100898A (en) Antitussive liquid compositions containing dyclonine
US20060269598A1 (en) Antihistaminic/Decongestant/Anticholinergic Compositions and Methods of Use
CN1022023C (zh) 含哌啶子基链烷醇衍生物的液体药物组合物的制备方法
CN1252720A (zh) 胃停留药物组合物
EP0315332A1 (en) Antitussive liquid compositions containing phenol
US20050053656A1 (en) Compositions and methods for treating pain
JPH09157162A (ja) イブプロフェンを溶解してなるかぜ薬軟カプセル及びその製造方法
US6586469B2 (en) Antihistaminic/antitussive compositions
CA2469736A1 (en) Diphenhydramine tannate solid dose compositions and methods of use
US20050202080A1 (en) In process conversion method for preparing tannate tablet, capsule or other solid dosage forms
EP0383481A2 (en) Anesthetic oral compositions
US20070248667A1 (en) Tannate Compositions and Methods of Use
CN1124451A (zh) 液体抗酸组合物
CA2372535A1 (en) Antitussive compositions
JP2004339211A (ja) 医薬組成物
US20030044461A1 (en) Antitussive/expectorant compositions
US6162833A (en) Photostable aqueous solution comprising benzyl alcohol derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee